Previous 10 | Next 10 |
BURLINGTON, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, t...
BURLINGTON, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John ...
BURLINGTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John ...
scPharmaceuticals press release (NASDAQ:SCPH): Q1 GAAP EPS of -$0.26. Cash and cash equivalents of $75.46M For further details see: scPharmaceuticals GAAP EPS of -$0.26
The shares of scPharmaceuticals (NASDAQ:SCPH) have added ~14% in the pre-market Monday after the clinical-stage pharma company announced that the FDA accepted its New Drug Application (NDA) for heart failure therapy, Furoscix. A furosemide formulation, Furoscix is designed for outpa...
FDA assigns PDUFA action date of October 8, 2022 Continuing to ramp up commercial readiness activities in advance of an anticipated Q4 2022 launch of FUROSCIX®, if approved Ended Q1 with cash, cash equivalents, restricted cash and investments of $65.6 million ...
PDUFA action date set for October 8, 2022 Company preparing for Q4 commercial launch, if approved BURLINGTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that hav...
On April 11, scPharmaceuticals (NASDAQ:SCPH) said it resubmitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval of Furoscix to treat decompensated heart failure. The company added that In addition, West Pharmaceutical Services (WST)...
BURLINGTON, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, ...
scPharmaceuticals press release (NASDAQ:SCPH): Q4 GAAP EPS of -$0.27 beats by $0.08. Cash, cash equivalents, restricted cash and investments of $75.5M. For further details see: scPharmaceuticals GAAP EPS of -$0.27 beats by $0.08
News, Short Squeeze, Breakout and More Instantly...
scPharmaceuticals Inc. Company Name:
SCPH Stock Symbol:
NASDAQ Market:
scPharmaceuticals Inc. Website:
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today an...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...
Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents o f $58.4 million Company to host investor conference call and web...